Sanbo Hospital Management (301293)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥320,537,369.42, representing a 7.66% increase compared to the same period last year[21]. - The net profit attributable to shareholders for Q3 2023 was ¥28,656,848.84, an increase of 16.99% year-on-year[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥30,085,691.37, reflecting a 30.00% increase compared to the previous year[21]. - Total operating revenue for Q3 2023 reached ¥960,305,219.68, an increase of 15.7% compared to ¥829,890,759.11 in the same period last year[47]. - Operating profit for Q3 2023 was ¥113,833,123.61, up from ¥87,971,626.26 in Q3 2022, reflecting a growth of 29.4%[48]. - Net profit for Q3 2023 was ¥81,202,524.61, compared to ¥66,097,433.79 in Q3 2022, representing a year-over-year increase of 22.8%[48]. - Earnings per share for Q3 2023 was ¥0.53, an increase from ¥0.48 in the same quarter last year[48]. - Total operating costs for Q3 2023 were ¥850,535,272.82, up from ¥747,461,238.75 in Q3 2022, indicating a rise of 13.8%[47]. - Tax expenses for Q3 2023 amounted to ¥25,696,102.61, compared to ¥21,175,128.93 in the previous year, reflecting an increase of 21.8%[48]. - The company reported a financial income of ¥10,685,535.55 in Q3 2023, compared to ¥4,918,315.91 in Q3 2022, showing significant growth[47]. Assets and Equity - The total assets as of the end of Q3 2023 reached ¥2,990,683,142.07, a 63.28% increase from the end of the previous year[21]. - The equity attributable to shareholders of the listed company was ¥2,324,422,576.77, which is a 93.48% increase year-on-year[21]. - Total assets increased to ¥2,990,683,142.07 from ¥1,831,659,252.82, marking a growth of 63.2%[45]. - Shareholders' equity attributable to the parent company increased by 93.48% compared to the end of the previous year, with an increase of 1,123.0277 million yuan due to raised funds and increased retained earnings[24]. - Cash and cash equivalents as of September 30, 2023, amounted to 925,846,230.32 yuan, up from 573,052,397.62 yuan at the beginning of the year[43]. - The company's total current assets reached 1,735,808,676.17 yuan, significantly higher than 714,840,342.77 yuan at the beginning of the year[43]. - The company reported a significant increase in accounts receivable, which rose to 85,013,822.90 yuan from 69,209,382.12 yuan[43]. Cash Flow - The cash flow from operating activities for the year-to-date was ¥170,894,245.87, showing a 43.10% increase compared to the same period last year[21]. - The net cash flow from operating activities increased by 43.10% year-to-date, with an increase of 51.4676 million yuan attributed to higher operating income[24]. - Operating cash flow for the period was 119,426,661.11 in the previous period[50]. - Total cash inflow from operating activities reached 849,484,829.35, reflecting a growth of approximately 15%[50]. - Cash outflow from operating activities was 730,058,168.24, indicating an increase of about 10%[50]. - Cash received from other operating activities was 23,025,043.80, reflecting a growth of about 33%[50]. - The company paid 44,671,711.79 in the previous period[50]. Investments and Acquisitions - The company completed the acquisition of 100% equity in Beijing Huibokang Medical Equipment Co., Ltd. for ¥560.30, enhancing its industry chain layout[11][12]. - The company is actively expanding its market presence with new projects in Kunming, Beijing, and Hunan, contributing to asset growth[24]. - The cash inflow from investment activities was 555,195,846.00, indicating a decrease of approximately 22%[50]. - Investment activities resulted in a net cash outflow of 177,500,002.17 in the previous period[50]. Shareholder Information - The company reported a total of 27,118 common shareholders at the end of the reporting period[8]. - The top ten shareholders include Zhang Yang with 10.59% ownership, indicating a concentrated ownership structure[27]. - The company distributed dividends totaling 4,687,405.00 in the previous period[51]. Research and Development - The company has maintained a strong focus on R&D for new products and technologies, enhancing its competitive edge in the market[24].